Skip to main content

EiRx, BioMérieux Pen PGx Alliance to Validate Each Other’s Dx, Rx Biomarkers

NEW YORK (GenomeWeb News) — EiRx Therapeutics and BioMérieux today said they plan to validate the diagnostic and therapeutic potential of their candidate tumor markers.
 
Terms of the alliance call for BioMérieux to see if proteins in EiRx’s biomarker panel can become components in new diagnostics for colorectal cancer. Meanwhile, EiRx will use its siRNA-driven platform to test BioMérieux’s colorectal biomarker panel as targets for new drug therapies.
 
During the evaluation phase of the collaboration, which will last up to 18 months, EiRx has granted BioMérieux an exclusive option to license and “exploit” diagnostic applications of its biomarker intellectual property. 
 
Similarly, BioMérieux has granted EiRx an exclusive option to license and “exploit” therapeutic applications of its own IP, and said it will develop companion diagnostics for any drug candidates developed by EiRx against targets proposed by BioMérieux. 
 
Financial details of the agreement were not disclosed.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.